SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
Related Questions
How will the Q2 financial results compare to consensus analyst forecasts?
Will there be any updates on the progress of key clinical trials or regulatory milestones?
What are the expected revenue and cash burn figures for Q2 2025?
Are there any new partnership or licensing announcements that could affect future cash flows?
Is there any change in the company’s capital structure, such as debt financing or equity issuances?
How does the valuation metrics (EV/Revenue, P/E) post‑update stack up against peer biotech companies?
How might the Q2 results influence the long‑term growth outlook for BioCardia's pipeline?
How does BioCardia's cash runway compare to its current burn rate and upcoming milestones?
What impact could the Q2 update have on the stock's short‑term price momentum?
What guidance is management providing for Q3 2025 and the full year?